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Abstract: Syringocystadenoma papilliferum (SCAP) is a benign
tumor most commonly located on the head and neck area often
associated with nevus sebaceus. In its usual location, the human
papillomavirus (HPV) DNA and mutations in the RAS/mitogen-
activated protein kinase signaling pathway have been detected in
SCAP. We studied 16 cases of SCAP in the anogenital areas and
buttock where this neoplasm is rare and attempted to find out
whether SCAP in these sites have different histopathological and
molecular biological features. It seems that there is no significant
difference between the morphology of anogenital SCAP and SCAP
in other locations. Several tumors in our cohort demonstrated
features resembling those seen in warts, but HPV DNA was not
found in these lesions. On the contrary, we identified DNA of HPV
high-risk types in some tumors without HPV-related morphology.
Our study confirms the role of HRAS and BRAF V600 mutations in
the pathogenesis of SCAP, including SCAP in the anogenital areas
and buttock.
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INTRODUCTION
Syringocystadenoma papilliferum (SCAP) is a rare
benign adnexal neoplasm occurring either sporadically or as
a secondary tumor in nevus sebaceus of Jadassohn. The
commonest affected site is the head and neck area.1 The trunk
and extremities are occasionally involved, whereas lesions
involving the groin, buttock, and anogenital SCAP have
rarely been reported.2,3 Histopathologically, SCAP appears
exo-endophytic, often crateriform lesion with a papillary
architecture formed by double-layered tubular structures com-
posed of cuboidal to columnar luminal cells, often showing
apocrine secretion surrounded by a peripheral layer of basal/
myoepithelial cells. Various hyperplastic and metaplastic
changes (mucinous metaplasia and squamous metaplasia)
and also malignant transformation have been described in
SCAP.4–8 The pathogenesis of SCAP remains unclear,
although both in sporadic cases and lesions arising in nevus
sebaceus the human papillomavirus (HPV) DNA2,9 and mu-
tations in the RAS/mitogen-activated protein kinase signaling
pathway have been detected.10,11 The above histopathological
and molecular changes have been found in SCAP in its usual
location in the head and neck area. Our aim was to study
SCAP in the anogenital area and buttock to find out whether
the lesions in these sites have different features.
MATERIAL AND METHODS
Case Inclusion/Exclusion
A search in the consultation and routine institutional files
of the authors between 1993 and 2017 yielded 243 cases of
SCAP, of which 15 lesions involved the anogenital area (penis,
mons pubis, vulva, and perianal area) and buttock. One case
has recently been seen in routine practice. Hematoxylin–eosin–
stained slides were reviewed to confirm the diagnosis, specif-
ically to exclude cases of hidradenoma papilliferum with
connection to the epidermis and plasma cell–rich infiltrate
imitating SCAP as previously reported.12–14 The
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histopathological findings were correlated with the clinical data
to confirm the location and appropriate clinicopathological
context.
Light Microscopic Studies
The number of tissue blocks available for review varied
from 1 to 3. The following histopathological features were
assessed: exophytic, verrucous and cystic alterations, differ-
ent types of epithelial cell metaplasia, basal cell hyperplasia,
and hyperplasia of luminal cells resulting in a cribriform
appearance.
All cases were also examined for the presence of HPV-
related features, using the criteria of Meisels for HPV
infection (perinuclear halos surrounding hyperchromatic,
enlarged angulated nuclei located in the superficial zones of
the epidermis). In addition, we looked for granular layer
disruption (abrupt alteration in the size, number, form, and
density of keratohyaline granules) and percentage of koilo-
cytosis in the spinous layer.9,15 Any other unusual features, if
present, were also recorded.
Twelve cases with available paraffin blocks/unstained
slides were studied immunohistochemically for p16 expres-
sion (R19-D; Ventana; RTU), using the Ventana Benchmark
XT automated stainer (Ventana Medical System Inc, Tucson,
AZ), according to the manufacturer’s protocol. Diffuse
nuclear and cytoplasmic staining was classified as positive
p16 staining. No positive cells and weak and focal positivity
in some cells were classified as p16-negative staining.
Molecular Genetic Studies
Thirteen lesions were subjected for molecular-genetic
studies, including HPV polymerase chain reaction (PCR) and
HRAS mutations. Twelve cases were analyzed for the pres-
ence of the BRAF V600 mutation.
For molecular-genetic studies, genomic DNA was
isolated from formalin-fixed, paraffin-embedded tissue using
QIAsymphony DNA Mini Kit (Qiagen, Hilden, Germany)
according to manufacturer’s protocol on QIAsymphony SP
device (Qiagen). Special precautions were taken to prevent
HPV DNA microcontamination. The quality of isolated DNA
was checked by PCR that amplifies set of control genes.16
TABLE 1. Sequences of HRAS Primers
Sequences of HRAS Primers (5- 30) Name of Primer
CACAAGGGAGGCTGCTGAC HRAS-exon 4 reverse
CTGATCCCATCCCTCCTTTC HRAS-exon 4 forward
GGGTCCCTGGCTAGCTGT HRAS-exon 3 reverse
CTCTCGCTTTCCACCTCTCA HRAS-exon 3 forward
CAGCCTCACGGGGTTCAC HRAS-exon 2 reverse
CCCACGGAAGGTCCTGAG HRAS-exon 4 forward
CCTATCCTGGCTGTGTCCTG HRAS-exon 1 reverse
CAGGAGACCCTGTAGGAGGA HRAS-exon 1 forward
TABLE 2. Summary of Clinicopathological and Genetic Findings in the Cohort







1 F/? Vulva 3, 4, 5, and deposits of mucin in
the epithelium
Neg Neg Neg/NA ND
2 F/23 Perianal 2 and 5 Neg HPV16+ NA/neg +
3 F/42 Vulva 1, 2, and 5 Neg Neg (NA) NA/neg +
4 F/95 Vulva and labium
majus
3, 4, 5, 6, and 7 ND ND ND ND
5 F/81 Vulva and labium
majus




Neg (NA) NA/neg +
6 F/78 Vulva 7 and 8 Neg Neg (NA) NA/neg +
7 M/60 Perianal 1, 5, and 8 ND HPV16+ NA/NA NA
8 F/59 Perianal 5 and desmoplasia Neg Neg c.182A . G, p.Gln61Arg/NA Neg
9 F/44 Perianal 2 and 7 ND ND ND ND
10 F/65 Right buttock 5 and 9 Neg Neg Neg/NA +
11 M/33 Right buttock 1 and 7 Neg
(patchy sq)
Neg NA/neg +
12 F/28 Left buttock 3 and 5 Neg HPV68§ NA/neg Neg
13 M/18 Buttock 3, 4, 7, and 8 Neg
(patchy sq)
Neg (NA) NA/neg +
14 F/34 Buttock 1 and 8 ND ND ND ND
15 M/54 Buttock — Neg Neg Neg/NA Neg
16 M/79 Buttock 3 Neg Neg Neg +
*1—exophytic; 2—cystic; 3—verrucous; 4—HPV-related morphology; 5—squamous metaplasia; 6—clear cell metaplasia; 7—cribriform structures; 8—basal cell hyperplasia.
†Sequencing analysis whole coding sequence of HRAS gene, including exon–intron junction.
‡Codons 12, 13, and 61.
§A very low quality of DNA, we cannot exclude the risk of false negativity for other HPV types.
F, female; M, male; NA, not available; ND, not done; neg (NA), no HPV virus found in the examined sample; however, the quality and quantity of DNA were very low, and
therefore, we cannot exclude the risk of false negative finding; patchy sq, patchy staining of the squamous component.
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The HPV DNA detection was performed using multiple
PCR primers from the L1, E1, and E6–E7 regions of the HPV
genome as previously described.17 In brief, primers CPSGB
and GP5+/GP6+ targeting the E1 and L1 regions of the HPV
genome were used for a wide-range detection of high-risk
(HR) and low-risk HPV types, and type-specific PCR detec-
tion of E6–E7 region of 6 most prevalent HR-HPV types,
namely types 16, 18, 31, 33, 35, and 45, was used to increase
sensitivity of HPV detection and to avoid negative finding
due to the possible process of HPV integration into the human
genome. Furthermore, an RHA kit HPV SPF10-LiPA25, ver-
sion 1 (Bio-medical Products, Rijswijk, the Netherlands), was
run to reveal possible multiple HPV types.
HRAS mutation detection was performed in compliance
with the DNA quality of the analyzed DNA. Studied were
cases in which more than 300 amplifiable base pairs of DNA
were available. The analysis of 4 exons of the HRAS gene was
performed by PCR using primers listed in Table 1. In cases
with a lower DNA quality, only hot spot mutation analysis of
exons 2 and 3 of HRAS was performed according to the article
by Roivainen et al.18 Amplified products were sequenced on
ABI Prism 3130xl (Applied Biosystems, Foster City, CA).
DNA sequences were compared with the reference sequence
by the online program BLAST.
The analysis of mutations in the BRAF gene (codon
600) was performed using the real-time PCR method by com-
mercial kit cobas 4800 BRAF V600 Mutation Test (Roche,
Pleasanton, CA) according to the manufacturer instructions.
RESULTS
Clinical Data
There were 11 women and 5 men, whose ages at the
time of diagnosis ranged from 18 to 95 years (median 54
years; mean 52.9 years). In one case, the age of patient
remained unknown. In all cases, the lesions were a solitary
tumor. Most neoplasms involved the buttock (43.8%) and the
vulva (31.3%); less frequent site was the perianal area (25%)
(Table 2). No features suggesting nevus sebaceus (linear
arrangement and congenital lesions) were mentioned in the
patients’ charts.
Histopathological Features
All tumors had a papillary architecture with a transition
from the glandular epithelium to the keratinizing squamous
epithelium at the skin surface (Fig. 1). A dense plasma cell
stromal infiltrate presented at the squamocolumnar junction.
The glandular component was lined by a luminal layer of
epithelial cuboidal to columnar cells surrounded by a layer
of basal/myoepithelial cells. Prominent cystic change of the
lesion identified in 3 (18.8%) cases. Five lesions (31.3%)
were markedly exophytic with an arboreal growth pattern of
the glandular elements. Three examples (cases 1, 4, and 13)
(18.8%) demonstrated features resembling those seen in warts
including acanthosis, papillomatosis, and HPV-associated
changes (Figs. 2A, B).
The most common type of epithelial metaplasia was
squamous (7 lesions; 43.8%). In one case, there was slight
atypia in the squamous epithelium that focally showed rather
basaloid cells that along with plentiful mitotic figures
occasioned a resemblance to undifferentiated vulvar intra-
epithelial neoplasia (Figs. 3A, B). One lesion exhibited focal
FIGURE 2. Squamous metaplasia
with atypia in SCAP (A). Note slight
atypia in the squamous epithelium,
basaloid cells, and mitotic figures
(arrows) (B).
FIGURE 1. SCAP. The tumor has a papillary architecture with
a transition from glandular epithelium to the keratinizing
squamous epithelium at the skin surface.
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clear cell change of the luminal epithelial cells. The hyper-
plasia of luminal cells, which results in the formation of crib-
riform structures, was observed in 5 cases (31.3%) (Fig. 4).
Four (25%) SCAP showed focal hyperplasia of basal/
myoepithelial cells. In one case, mucin deposit was found
in the basal part of the squamous epithelium.
Immunohistochemical Data
Among 12 lesions immunohistochemically available
for p16 expression, all were scored as p16-negative (3 cases
demonstrated a patchy staining of the squamous component)
(Table 2).
Molecular Genetic Findings
DNA of HPV HR types was identified by PCR in 3
(23.1%) of the 13 analyzed cases, including HPV16 (2 cases)
and HPV68 (1 case) (Table 2).
All but one case were negative for HRAS mutations. A
missense mutation p.Gln61Arg in the proto-oncogene HRAS
was identified in 1 lesion (7.7%) (Table 2).
BRAF V600 was detected in 8 of 12 cases (66.7%)
(Table 2).
DISCUSSION
We have described 16 cases of SCAP in the anogenital
areas and buttock. Albeit we have not studied a control group
of SCAP in its usual location, it seems that there is no
significant difference between the morphology of anogenital
SCAP and SCAP in other locations. Such histological
variations as epithelial metaplasia, cystic alteration, and
hyperplastic changes with the formation of cribriform struc-
tures have been described in SCAP involved the head and
neck, trunk and extremities.1
In addition, some SCAP in its usual location and
neoplasms affected the anogenital area and buttock have
viral wart-like changes presenting as verrucous tumors.
Among 18 cases of SCAP with such a morphology described
in the literature, the most common location was the cheek
(16.7%), scalp (16.7%), and lower extremity (16.7%) fol-
lowed by the buttock (11.1%), neck (11.1%), vulva (5.5%),
sacral area (5.5%), back (5.5%), аreola (5.5%), and eyelid
(5.5%).2,19–25
The cause of such contiguous verrucous proliferations
in SCAP is unclear. Some authors have suggested a possible
role of HPV infection. Skelton et al2 reported the presence of
HPV 6/11 in the verrucous SCAP of the buttock identified by
in situ hybridization. Carlson et al9 detected HPV 16 type in 1
case and HPV 38 type in a second case of 4 SCAP associated
with nevus sebaceus. In our cohort, we failed to identify HPV
by p16 immunostaining in all analyzed cases. However, DNA
of HPV HR types was identified by PCR in 3 (23.1%) of the
13 analyzed cases, including HPV 16 type (2 cases) and HPV
68 type (1 case). None of these cases demonstrated clear-cut
HPV-related cytomorphology (unequivocal koilocytes).
However, we noticed features suggesting HPV infection
(wart-like acanthosis and papillomatosis) in 3 (18.8%) cases.
BRAF V600E and HRAS mutations are most common
molecular alterations found in sporadic SCAP.11,26,27 Shen
et al investigated 23 cases of sporadic SCAP with only one
case located in the gluteal area. The detection rate of HRAS
mutations in their study was 26.1% (6 cases), whereas BRAF
V600E mutations were identified in 52.2% (12 cases), which
included a neoplasm located in the gluteal area.11 Levinsohn
et al27 studied 10 cases of sporadic SCAP and detected HRAS
pG13R mutations and BRAF V600E mutation in 10% and
40% of lesions, respectively.
An immunohistochemical expression of BRAF V600E
protein has been studied by Friedman et al in 11 cases of
FIGURE 3. Wart-like changes in
SCAP, including acanthosis, papil-
lomatosis (A), and HPV-associated
changes (B).
FIGURE 4. Hyperplasia of luminal cells resulting in cribriform
appearance.
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sporadic SCAP. The positive staining was identified in 7
(63.6%) cases.25
The detection rate of HRAS mutation in our cohort was
7.7%, which is lower compared with the previously reported
material (10%–26.1%), while the frequency of BRAF muta-
tions (66.7%) was a little more than the published rates of
40%–63.6%.
In conclusion, we present a series of sporadic SCAP
located in the buttock and anogenital area detailing a spectrum
of morphological changes that may occur in these lesions.
Several tumors demonstrated features resembling those seen
in warts, but HPV DNA was not found in these lesions. On
the contrary, we identified DNA of HPV HR types in some
tumors without HPV-related morphology. Our study confirms
the role of HRAS and BRAF V600 mutations in the pathogen-
esis of SCAP, including SCAP in the anogenital areas and
buttock.
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